In this short interview with Fierce Pharma, AGC Biologics' Dieter Kramer, Senior Vice President and General Manager of our Heidelberg, Germany site, discusses the upcoming manufacturing crunch in microbial production as demand increases. As the leader of the microbial center of excellence for our global network, he offers unique insights on the market, such as microbial products make up 28-30% of the API market, and this segment is actively growing. He estimates a 50% production shortfall in the market. In addition, he notes that ~70% of the current capacity is held by only 10 companies. And half of these are developing their own products, creating a conflict of interest. Watch Dieter's interview below to learn more!
AGC Biologics offers large-scale microbial capacity for late-phase and commercial projects. We have a new program offering priority access, set pricing, and predefined timelines for up to 10,000 L of capacity to meet your clinical and commercial timelines.
Click below to watch:
.jpg)